Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

Also called NCT02928094

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Angionetics Inc. (from the registry)
Registry
  • NCT NCT02928094
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02928094. Randomized; triple masking; primary purpose treatment. Start 2023-01-01 (anticipated); primary completion 2024-03-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia
Acronym
AFFIRM
Condition
Angina, Stable
Intervention (Biological)
Ad5FGF-4
Intervention (Biological)
Placebo
Lead sponsor
Angionetics Inc. (class: industry)
Collaborator
Huapont Life Sciences (class: not stated)

Record details

Record id
cardio:ct-nct02928094
Content hash
59c4e88acb435ed6c7ef2a9819cfd40cb5b3f62b2a0a2b2feb6e1b2f272eb212